The goal of this application contains two parts. The first is to determine if the development of P-glycoprotein associated multidrug resistance (MDR) affect the clinical response of a patient to cancer chemotherapy. The second part is to investigate mechanisms regulating P-glycoprotein expression in normal and malignant cells. In model systems, P-glycoprotein has been shown to be causative of MDR and is thought to function as an energy-dependent drug efflux pump. Although other mechanisms of MDR have been proposed, the P-glycoprotein-mediated form is the best documented and appears to have clinical relevance. Since P-glycoprotein expression appears to be a reliable molecular marker for the MDR phenotype, one specific aim is to develop sensitive and specific reagents for the immunohistochemical localization of P- glycoprotein in tumor biopsy samples. One approach which has met with success is to map the epitopes of P-glycoprotein monoclonal antibodies and to use synthetic competing peptides to define epitope-specific staining. This approach will be extended to a number of P-glycoprotein monoclonal antibodies. Such reagents will be used for correlating P-glycoprotein expression and clinical response. The second specific aim is to determine if chemosensitizing agents azidopine and cyclosporin A interact with P-glycoprotein at a similar domain. Such knowledge will form the basis for a molecular understanding of how such structurally different molecules are able to reverse the MDR phenotype. The third specific aim is to study the mechanisms of increased P- glycoprotein expression in tumor cell lines. We particularly wish to investigate the observation that a significant proportion of patients present with P-glycoprotein positive tumors even prior to chemotherapy. This may provide insights into why some tumors are not responsive to chemotherapy from the outset. We believe that accomplishment of the specific aims described in this application will add significantly to our knowledge of malignant development and therapeutic efficacy in human cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA037130-09
Application #
3174835
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1990-07-01
Project End
1993-06-30
Budget Start
1992-07-01
Budget End
1993-06-30
Support Year
9
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Ontario Cancer Institute
Department
Type
DUNS #
City
Toronto
State
Country
Canada
Zip Code
Chan, H S; Grogan, T M; Haddad, G et al. (1997) P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst 89:1706-15
Chan, H S; Gallie, B L; DeBoer, G et al. (1997) MYCN protein expression as a predictor of neuroblastoma prognosis. Clin Cancer Res 3:1699-706
Shapiro, A B; Ling, V (1997) Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem Pharmacol 53:587-96
Chan, H S; Haddad, G; Zheng, L et al. (1997) Sensitive immunofluorescence detection of the expression of P-glycoprotein in malignant cells. Cytometry 29:65-75
Chan, H S; Lu, Y; Grogan, T M et al. (1997) Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein. Cancer Res 57:2325-30
Chan, H S; Grogan, T M; DeBoer, G et al. (1996) Diagnosis and reversal of multidrug resistance in paediatric cancers. Eur J Cancer 32A:1051-61
Gallie, B L; Budning, A; DeBoer, G et al. (1996) Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 114:1321-8
Chan, H S; DeBoer, G; Thiessen, J J et al. (1996) Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. Clin Cancer Res 2:1499-508
Chan, H S; DeBoer, G; Haddad, G et al. (1995) Multidrug drug resistance in pediatric sarcomas. Hematol Oncol Clin North Am 9:889-908
Muller, C; Laurent, G; Ling, V (1995) P-glycoprotein stability is affected by serum deprivation and high cell density in multidrug-resistant cells. J Cell Physiol 163:538-44

Showing the most recent 10 out of 54 publications